These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27548656)

  • 1. Recently discovered EZH2 and EHMT2 (G9a) inhibitors.
    Soumyanarayanan U; Dymock BW
    Future Med Chem; 2016 Sep; 8(13):1635-54. PubMed ID: 27548656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry.
    Wei L; Mei D; Hu S; Du S
    Future Med Chem; 2024 Aug; 16(15):1561-1582. PubMed ID: 39082677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
    Wu D; Zeng X; Zhao Y; Qin M; Gong P
    Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.
    Rogawski DS; Grembecka J; Cierpicki T
    Future Med Chem; 2016 Sep; 8(13):1589-607. PubMed ID: 27548565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tazemetostat: First Approval.
    Hoy SM
    Drugs; 2020 Apr; 80(5):513-521. PubMed ID: 32166598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
    Dockerill M; Gregson C; O' Donovan DH
    Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
    Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
    Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
    J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
    Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
    Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2,2- dimethylbenzopyran derivatives containing pyridone structural fragments as selective dual-targeting inhibitors of HIF-1α and EZH2 for the treatment of lung cancer.
    Xu H; Zhang J; Zhuang J; Chen Y; Chen L; Wang J; Cao R; Liu F; Wang K; Zhang X; Wang L; Chen G
    Bioorg Chem; 2024 Jun; 147():107419. PubMed ID: 38703440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Dual Lysine Methyltransferase G9a and EZH2 Inhibitors with In Vivo Efficacy against Malignant Rhabdoid Tumor.
    Shi Y; Zhang Q; Zhang M; Chen Y; Sun J; Chen L; Liu S; Liu Z; Yang J; Wu C; Zheng Z; Wang L; Chen G
    J Med Chem; 2023 Apr; 66(8):5685-5702. PubMed ID: 37021456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
    Yang C; Li B; Feng Z; Li H; Yang H; Yang Z; Liu L; Shi Q; Wang H; Chen ZZ; Huang X; Wang J; Wang Y
    J Med Chem; 2024 Sep; 67(18):16072-16087. PubMed ID: 39008565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.
    Kung PP; Rui E; Bergqvist S; Bingham P; Braganza J; Collins M; Cui M; Diehl W; Dinh D; Fan C; Fantin VR; Gukasyan HJ; Hu W; Huang B; Kephart S; Krivacic C; Kumpf RA; Li G; Maegley KA; McAlpine I; Nguyen L; Ninkovic S; Ornelas M; Ryskin M; Scales S; Sutton S; Tatlock J; Verhelle D; Wang F; Wells P; Wythes M; Yamazaki S; Yip B; Yu X; Zehnder L; Zhang WG; Rollins RA; Edwards M
    J Med Chem; 2016 Sep; 59(18):8306-25. PubMed ID: 27512831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
    Lue JK; Amengual JE
    Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights for the design of protein lysine methyltransferase G9a inhibitors.
    Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
    Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
    Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
    Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancer of zeste homolog 2 (EZH2) inhibitors.
    Gulati N; Béguelin W; Giulino-Roth L
    Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
    Katayama K; Ishii K; Tsuda E; Yotsumoto K; Hiramoto K; Suzuki M; Yasumatsu I; Igarashi W; Torihata M; Ishiyama T; Katagiri T
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127475. PubMed ID: 32781218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.